Medical - Distribution
Compare Stocks
2 / 10Stock Comparison
GRDN vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Distribution
GRDN vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Distribution | Medical - Distribution |
| Market Cap | $2.30B | $92.15B |
| Revenue (TTM) | $1.46B | $403.43B |
| Net Income (TTM) | $53M | $4.76B |
| Gross Margin | 20.2% | 3.6% |
| Operating Margin | 6.4% | 1.5% |
| Forward P/E | 29.6x | 19.3x |
| Total Debt | $37M | $7.39B |
| Cash & Equiv. | $66M | $5.69B |
GRDN vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| Guardian Pharmacy S… (GRDN) | 100 | 216.0 | +116.0% |
| McKesson Corporation (MCK) | 100 | 152.2 | +52.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GRDN vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
GRDN carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 17.9%, EPS growth 144.1%, 3Y rev CAGR 16.8%
- 17.9% revenue growth vs MCK's 16.2%
- 3.6% margin vs MCK's 1.2%
MCK is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 17 yrs, beta 0.04, yield 0.4%
- 348.1% 10Y total return vs GRDN's 126.7%
- Lower volatility, beta 0.04, current ratio 0.90x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 17.9% revenue growth vs MCK's 16.2% | |
| Value | Lower P/E (19.3x vs 29.6x), PEG 0.49 vs 1.58 | |
| Quality / Margins | 3.6% margin vs MCK's 1.2% | |
| Stability / Safety | Beta 0.04 vs GRDN's 1.04 | |
| Dividends | 0.4% yield; 17-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +40.5% vs MCK's +4.6% | |
| Efficiency (ROA) | 13.4% ROA vs MCK's 5.7%, ROIC 35.8% vs 5.4% |
GRDN vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
GRDN vs MCK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
GRDN leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK is the larger business by revenue, generating $403.4B annually — 277.1x GRDN's $1.5B. Profitability is closely matched — net margins range from 3.6% (GRDN) to 1.2% (MCK). On growth, MCK holds the edge at +6.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.5B | $403.4B |
| EBITDAEarnings before interest/tax | $112M | $6.8B |
| Net IncomeAfter-tax profit | $53M | $4.8B |
| Free Cash FlowCash after capex | $70M | $6.0B |
| Gross MarginGross profit ÷ Revenue | +20.2% | +3.6% |
| Operating MarginEBIT ÷ Revenue | +6.4% | +1.5% |
| Net MarginNet income ÷ Revenue | +3.6% | +1.2% |
| FCF MarginFCF ÷ Revenue | +4.8% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.2% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +40.0% | +37.0% |
Valuation Metrics
MCK leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 29.2x trailing earnings, MCK trades at a 37% valuation discount to GRDN's 46.5x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs GRDN's 2.48x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||
|---|---|---|
| Market CapShares × price | $2.3B | $92.1B |
| Enterprise ValueMkt cap + debt − cash | $2.3B | $93.8B |
| Trailing P/EPrice ÷ TTM EPS | 46.51x | 29.25x |
| Forward P/EPrice ÷ next-FY EPS est. | 29.62x | 19.28x |
| PEG RatioP/E ÷ EPS growth rate | 2.48x | 0.75x |
| EV / EBITDAEnterprise value multiple | 20.40x | 18.74x |
| Price / SalesMarket cap ÷ Revenue | 1.59x | 0.26x |
| Price / BookPrice ÷ Book value/share | 10.54x | — |
| Price / FCFMarket cap ÷ FCF | 28.47x | 17.63x |
Profitability & Efficiency
GRDN leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $25 for GRDN.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +25.4% | +3.0% |
| ROA (TTM)Return on assets | +13.4% | +5.7% |
| ROICReturn on invested capital | +35.8% | +5.4% |
| ROCEReturn on capital employed | +41.5% | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.17x | — |
| Net DebtTotal debt minus cash | -$28M | $1.7B |
| Cash & Equiv.Liquid assets | $66M | $5.7B |
| Total DebtShort + long-term debt | $37M | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | 129.16x | 33.79x |
Total Returns (Dividends Reinvested)
GRDN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $22,675 for GRDN. Over the past 12 months, GRDN leads with a +40.5% total return vs MCK's +4.6%. The 3-year compound annual growth rate (CAGR) favors GRDN at 31.4% vs MCK's 27.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +22.9% | -8.5% |
| 1-Year ReturnPast 12 months | +40.5% | +4.6% |
| 3-Year ReturnCumulative with dividends | +126.7% | +106.4% |
| 5-Year ReturnCumulative with dividends | +126.8% | +286.9% |
| 10-Year ReturnCumulative with dividends | +126.7% | +348.1% |
| CAGR (3Y)Annualised 3-year return | +31.4% | +27.3% |
Risk & Volatility
Evenly matched — GRDN and MCK each lead in 1 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than GRDN's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GRDN currently trades 87.7% from its 52-week high vs MCK's 75.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.04x | 0.04x |
| 52-Week HighHighest price in past year | $41.36 | $999.00 |
| 52-Week LowLowest price in past year | $19.17 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +87.7% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 47.4 | 16.2 |
| Avg Volume (50D)Average daily shares traded | 461K | 757K |
Analyst Outlook
MCK leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates GRDN as "Buy" and MCK as "Buy". Consensus price targets imply 33.8% upside for MCK (target: $1007) vs 4.7% for GRDN (target: $38). MCK is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $38.00 | $1006.50 |
| # AnalystsCovering analysts | 3 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | 0 | 17 |
| Dividend / ShareAnnual DPS | — | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.3% | +3.4% |
GRDN leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MCK leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
GRDN vs MCK: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is GRDN or MCK a better buy right now?
For growth investors, Guardian Pharmacy Services, Inc.
(GRDN) is the stronger pick with 17. 9% revenue growth year-over-year, versus 16. 2% for McKesson Corporation (MCK). McKesson Corporation (MCK) offers the better valuation at 29. 2x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate Guardian Pharmacy Services, Inc. (GRDN) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GRDN or MCK?
On trailing P/E, McKesson Corporation (MCK) is the cheapest at 29.
2x versus Guardian Pharmacy Services, Inc. at 46. 5x. On forward P/E, McKesson Corporation is actually cheaper at 19. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Guardian Pharmacy Services, Inc. 's 1. 58x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — GRDN or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to +126. 8% for Guardian Pharmacy Services, Inc. (GRDN). Over 10 years, the gap is even starker: MCK returned +348. 1% versus GRDN's +126. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GRDN or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.
04β versus Guardian Pharmacy Services, Inc. 's 1. 04β — meaning GRDN is approximately 2314% more volatile than MCK relative to the S&P 500.
05Which is growing faster — GRDN or MCK?
By revenue growth (latest reported year), Guardian Pharmacy Services, Inc.
(GRDN) is pulling ahead at 17. 9% versus 16. 2% for McKesson Corporation (MCK). On earnings-per-share growth, the picture is similar: Guardian Pharmacy Services, Inc. grew EPS 144. 1% year-over-year, compared to 14. 9% for McKesson Corporation. Over a 3-year CAGR, GRDN leads at 16. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GRDN or MCK?
Guardian Pharmacy Services, Inc.
(GRDN) is the more profitable company, earning 3. 4% net margin versus 0. 9% for McKesson Corporation — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRDN leads at 6. 1% versus 1. 2% for MCK. At the gross margin level — before operating expenses — GRDN leads at 19. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GRDN or MCK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Guardian Pharmacy Services, Inc. 's 1. 58x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, McKesson Corporation (MCK) trades at 19. 3x forward P/E versus 29. 6x for Guardian Pharmacy Services, Inc. — 10. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MCK: 33. 8% to $1006. 50.
08Which pays a better dividend — GRDN or MCK?
In this comparison, MCK (0.
4% yield) pays a dividend. GRDN does not pay a meaningful dividend and should not be held primarily for income.
09Is GRDN or MCK better for a retirement portfolio?
For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
04), +348. 1% 10Y return). Both have compounded well over 10 years (MCK: +348. 1%, GRDN: +126. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GRDN and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.